Aconitum C20-diterpenoid Alkaloid Derivatives Regulate the Growth and Differentiation of Cord Blood Derived Human Hematopoietic Stem/Progenitor Cells
Version of Record online: 6 JAN 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Volume 26, Issue 8, pages 1262–1264, August 2012
How to Cite
Hazawa, M., Wada, K. and Kashiwakura, I. (2012), Aconitum C20-diterpenoid Alkaloid Derivatives Regulate the Growth and Differentiation of Cord Blood Derived Human Hematopoietic Stem/Progenitor Cells. Phytother. Res., 26: 1262–1264. doi: 10.1002/ptr.3718
- Issue online: 22 JUL 2012
- Version of Record online: 6 JAN 2012
- Manuscript Accepted: 2 NOV 2011
- Manuscript Received: 16 JUN 2011
- Aconitum C20-diterpenoid alkaloid;
- hematopoietic stem/progenitor cells (HSPCs);
- structure–activity relationship (SAR)
The pharmacological activity of Aconitum alkaloids depends on their fundamental structure. While C19-norditerpenoid alkaloids present significant toxicity to the central nervous system, C20-diterpenoid alkaloids have reduced toxicities. However, there is little information regarding the precise pharmacological properties of C20-diterpenoid alkaloids. C20-diterpenoid alkaloid derivatives have explicit structure–activity relationships targeting various tumor cells, which depend on the C11-substrate. However, the present study showed that C6-derivatives additively or synergistically sustained proliferation of CD34+ hematopoietic stem/progenitor cells derived from the placental/umbilical cord blood. It revealed that identical structures belonging to C20-diterpenoid alkaloids surprisingly have opposing proliferative effects depending on the derivatization sites (C6 versus C11). Copyright © 2012 John Wiley & Sons, Ltd.